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Abstract 
Background: Hemoglobin-associated disorder is a different group of recessive genetic diseases. which consist 
of the structural hemoglobin variants and the thalassemia.Aim of the study: - to characterize the spectrum of 
beta globin gene mutations  in patients with beta- thalassemia who are registered in thalassemia centers, Wasit, 
Iraq using PCR - based DNA diagnostic techniques.Patients and methods:The genomic DNA was extracted 
from 106 Iraqi patients with β-thalassemia major and intermedia from unrelated families and (50) healthy 
numbers as control were collected from Al-Karama  Teaching Hospital, in Wasit  province, to detect mutation 
using PCR - based DNA diagnostic techniques. .  Results: of 106 thalassemia patients, 35 (33%) of patients with 
no mutation detection, IVS 1.116 [T>G] mutation was detected in 42 patients ( 39.6%), followed by IVS 1.110 
[G>A], which was detected in 11 (10.4%) patients.Conclusions: Many mutations recorded a high frequency due 
to close relative marriage. By analyzing many mutations in β-globin gene leading to defect in beta chains play 
crucial role in drawing mutation frequency and their distribution in our society. 
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Introduction 
In genetic diseases, genetic factors play an important role in their etiology. (1) Hemoglobin-associated disorder 
are a different group of recessive genetic diseases which consist of the structural hemoglobin variants and the 
thalassemia.  These disorders can occur at high carrier incidences in the malaria-endemic regions of the world 
and are region-specific, due to the distinctive sort of structural variants and thalassemia mutation. (2) 
Thalassemia’s are a group of haemoglobinopathic disorders in which a hemoglobin suffers from defect in β-
globin polypeptide chains. (3) The clinical appearances are wide ranged from a symptomatic hypochromic and 
microcytosis to deep fatal anemias in utero or in early years of life if not got proper medication. Taking in 
account that about 7% of the world population are carries of a globin gene mutation. (4) Βeta (β)-thalassemia is 
an autosomal recessive disorder initiated solely by alteration in the β -globin gene which is sited in chromosome 
11 on the short arm. (5) It is branded by micro-cytosis and hemolytic anemias which result from interruption of 
the normal synthesis of the β - globin chains of hemoglobin. (6, 7) Recently, more than 1000 mutations have 
been recognized that have diverse effect on β -subunit and cause β –thalassemia. (5, 8) These mutations have a 
geographical pattern with racial origin and not eventually distributed. Some mutations maybe a common 
mutation, others are rare. (9,10,11) Mutations have been reported to interfere with the transcription of the β–
globin such as nucleotide substitutions and/or frame shifts of the insertion/deletion gene, splicing procedures and 
translation of mRNA β -globin gene, resulting in either totally deficiency or reduction of creation of β -globin 
chains. (7) Modern molecular techniques provide rich information about the nature of mutations and their 
distribution within world population. (7) The spectra of the β-thalassemia mutations have been determined for 
the Mediterranean, Asian, Indian, Chinese and many other populations, and approximately, 80 million persons 
are carrier of the thalassemia trait and the percentage of carriers is increasing all over the world (12). 
Aim of the study: -  It is to characterize the spectrum of beta globin gene mutations in Wasit in patients with 
beta- thalassemia who are registered in thalassemia centers,  in Wasit  province using PCR - based DNA 
diagnostic techniques.  
Patients and methods  
This study has involved (106) Iraqi patients with β-thalassemia major and intermedia from unrelated families 
and (50) healthy numbers as control were collected from Al-Karama Teaching Hospital, in Wasit  Province. 
These patients previously diagnosed based on standard symptoms and confirmed by Hb 
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electrophoresis and other parameters include HCV and MCV conducted in the same hospital laboratories.  
Venous blood sample (5-10mL) was collected from each patient with β-thalassemia. Each blood sample was 
divided into two tubes: 
- EDTA tubes for molecular studies. 
- The serum obtained by placing the blood in gel-plain plastic tube and  let clot made at 37C° for 5 minutes then 
centrifuged. The tubes centrifuged at 5000 rpm for 5 minutes, serum was collected and kept in freezer until used. 
The genomic DNA was extracted from the whole blood collected in EDTA anticoagulant tubes were used using 
AccuPrep® Genomic DNA Extraction Kit. 
Primers were supplied by Bioneer Company, lyophilized product at different concentrations. 
Lyophilized primers were dissolved in a free DNase/RNase water as recommended by the manufacturer and then 
leave at water bath to dissolve completely. This will give final concentration of (100 pmol/µl), as stock solution. 
Each primer was diluted to 20 pmol/ µL concentration as aliquots and kept freeze until used as work 
solution).Statistical analysis used SPSS version 20 software. P value 0.05 or less consider significant. 
In this work, two methods of mutation detection were adopted to cover most common mutations in the 
Middle East area. First one is based on the reverse-hybridization of the amplified ß-globin gene to 
oligonucleotide probes. The second method is multiplex ARMS using different set of primers for normal and 
mutant with common primer, and pairs of control primer.. 
Results 
In this work, two methods of mutation detection were adopted to cover most common mutations in the Middle 
East area. First one is based on the reverse-hybridizationof the amplified ß-globin gene to oligonucleotide probes. 
The second method is multiplex ARMS using different set of primers for normal and mutant with common 





Figure (1) represent agarose gel electrophoresis of PCR amplification  using  MARMS-PCR 1000bp molecular 
weight marker. (A) represent the first set of MARMS, (B) represent gel analyzer software screen for different 
product of  MARMS-PCR groups in one gel.  
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Of  (106)  patients with thalassemia who treated in thalassemia uniting ALKut Hospital, gene mutation 
done as well as complete blood picture. Same investigation were done to 50 normal health condition. The mean 
age of the patient is 13.9 years with range (2-52) years. Table No. One shows the descriptive values of the 
patients with thalassemia regarding blood indices. The mean of hemoglobin was 8.8 g/dl, mean of RBC was 3.5 
×10 12. The mean of MCV (mean corpuscular volume) was55fL, mean of MCH (mean corpuscular hemoglobin 
was 21 pg , MCHC ( mean corpuscular hemoglobin concentration was 28 g/dl.  






Hb(g/dl ) PCV(L/L) Platelet(×10 
9) 
MCV(fL) MCH(pg) MCHC(g/dl) 
Mean 11.9 3.5 8.8 25 308 55 21 28 
Median 8.2 3.1 9.0 26.3 303 65 24 29 
Std. 
Deviation 
11.6 0.5 2.0 32.259 159 4.8 3.5 1.2 
Minimum 3.2 1.4 3.1 11 32 65 20 26 
Maximum 81.1 3.6 11.1 32 1030 78 29 30 
Table No. (2): shows the statistical difference between patients and controls regarding blood indices, 
there is highly statistical difference between two groups regarding Hb, RBCs, MCV and MCH (p. value 0.001). 
And statistical difference in PCV and  MCHC (p. value 0.01, 0.02) respectively. There is no statistical 
difference in WBC and platelets (p. value 0.4, 0.5) respectively 
Table No. 2: comparison between patients and control in hematological values.  
Item  Patients mean± SD (106) Controls mean±SD(50) P. value 
WBC (×10 9) 11.9± 11.6 10.2±12.1 0.4 
RBC(×10 12) 3.5 ± 0.5 4.6 ± 0.7 0.001 
Hb(g/L) 8.8 ± 2.0 11.2 ±2.9 0.001 
PCV(L/L) 25 ± 32.2 36 ±0.07 0.01 
Platelet(×10 9) 308 ±159 290±150 0.5 
MCV(fL) 55 ±4.8 79.2 ±5.3 0.001 
MCH(pg) 21±3.5 24.4 ±5.3 0.001 
MCHC(g/dl) 28±1.2 30.5 ±11.934 0.02 
Male constitute about 58% of the thalassemia patients, the family history of thalassemia in analyzed 
thalassemia patients, about three quarters of thalassemia patients had family history of thalassemia 74%. 
Table No (3):shows demographics data regarding thalassemia types, consanguinity, gender, family 
history of thalassemia and blood group of analyzed thalassemia patients. More than two third of the patients 
were thalassemia major (69%), majority of the patients (85%)had consanguine marriage. 
Table No.3: demographic data of thalassemia patients  
Items Frequency Percentage 
Thalassemia type   
Major 73 68.9 
intermedia 33 31.1 
consanguinity   
Yes 90 84.9 
No 16 15.1 
Sex   
Male 61 57.5 
Female 45 42.5 
family history   
Yes 78 73.6 
No 28 26.4 
Total 106 100.0 
For all control group, no mutation was detected during mutation detection process, while for 106 
thalassemia patients, many types of mutation were detected as shown in table number five. IVS 1.116 [T>G] 
mutation was detected in 42 patients ( about 40%), IVS 1.110 [G>A] mutation was the second  one in frequency 
and was detected in 11 patients (10.4%). No mutation was detected in 35 patients. -30 [T>A], Codon 39 [ C>T], 
IVS 1.5 [A>C] mutation were detected in one patient for each. Because of low frequency and statistical purpose, 
all of the mutation with 1% consider as others. Table No. 4.  
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Table No. 4: mutation frequency of 106 thalassemia patients  
Mutations Frequency Percent 
IVS 1.116 [T>G] 42 39.6 
IVS 1.110 [G>A] 11 10.4 
IVS 1.5 [G>C] 7 6.6 
Codon 8/9 (+G) 3 2.8 
c.315+1G>A 3 2.8 
codon5[-CT] 3 2.8 
c.17_18delCT 2 1.9 
-30 [T>A] 1 .9 
Codon 39[C>T] 1 .9 
IVS 1.5 [A>C] 1 .9 
ND 35 33 
Total 106 100.0 
Table No five shows the association between family history of thalassemia and mutation, about three 
quarters of patients with IVS 1.116 [T>G], All patients with others mutation had family history 100%). In spite 
of P. value statistically not significant, but this need attention.  











'codon5[-CT] Others P. 
value 
no 10 (23.8) 4 (36.4) 2(28.6) 2(66) 1  (33.3) 0(0)  
yes 32(76.2) 7 (63.6) 5(71.4) 1(33.3) 2  (66.7) 5(100) 0.9 
Total  42  (100) 11(100) 7  (100) 3  (100) 3  (100) 5(100)  
Table No six  shows the Association between consanguine state of patient’s father and mother and 
mutation types. IVS 1.5 [G>C] and others mutation were detected in (100%) of patients with consanguinity 
marriage. More than (80%) patients with mutation IVS 1.116 [T>G], and IVS 1.110 [G>A], mutation were had 
consanguine marriage, with P. value 0.7. 
Table No 6: association between mutations types and consanguinity 












no 5(11.9) 2(18.2) 0  (.0) 1  (33.3) 1 (33.3) 0(0)  
yes 37(88.1) 9(81.8) 7(100) 2  (66.7) 2 (66.7) 5(100) 0.7 
 42 (100) 11(100) 7(100) 3  (100) 3  (100) 5(100)  
Table No (7) describes the Association between thalassemia types and mutation. More types of 
mutations are more common in thalassemia major, all analyzed patients whom had IVS and 1.5 [G>C]  
mutations were thalassemia major (100%). While more than (70%) patients with  IVS 1.116 [T>G] mutation 
were thalassemia major. All patients with  c.315+1G>A  mutation were  thalassemia  intermedia (100%). With P. 
value  0.01. 











Others P. value 
Intermedia 11(26.2) 5(45.5) 0(0) 1 (33.3) 0 (0) 3 (60)  
major 31(73.8) 6(54.5) 7(100) 2 (66.7) 3 (100) 2(40) 0.01 
Total 42 (100) 11(100) 7(100) 3 (100) 3 (100) 5(100)  
The relationship between genders and mutation types were describe in table No (8) 'IVS 1.116 [T>G] 
mutation which is more common in male gender (66.7%). While 'codon5[-CT] mutation more common in 
female.  
 
Table No 8: association between mutations types and gender   








Others P. value 
female 14(33.3) 6(54.5) 4(57.1) 2 (66.7) 2 (66.7) 1(20)  
male 28(66.7) 5(45.5) 3(42.9) 1 (33.3) 1 (33.3) 4(80) 0.6 
Total  42 (100) 11(100) 7 (100) 3 (100) 3 (100) 5(100)  
 
Discussion 
The gene analysis play important role In diagnosis as well as treatment of thalassemia. For 106 beta thalassemia 
patients with mean age 13.9 years, complete blood picture was done, which shown mean of blood indices (Hb, 
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RBCs, MCV, MCHC, MCH) as well as WBC and platelets mean. The mean of WBC and platelets are ranged 
with normal limits, while others parameters are lower than whatever mention in textbooks, (13).  
As thalassemia syndrome as one cause of hypochromic microcytic anemia all blood indices are below 
normal ranges. As comparison in blood indices between 106 analyzed thalassemia patients and 50 controls there 
is significant statistical difference in RBCs, Hb ,MCV, MCH. P value (0.001) and P. value is also statically 
different (0.01, 0.02) for PCV and MCHC respectively. These differences are compatible with what written in 
literatures, (13).   
Although the thalassemia is autosomal recessive disease, the sex disturbed is equally in both male and 
female, but in this study the Male to female ratio is 1.3:1 which may reflect the community nature.  As our 
culture is Eastern community, Since inbreeding is a high percentage of our society, this explains the high 
proportion of patients who have a family history of the disease, as consanguinity marriage percent ( 84%), and 
family history of thalassemia (73.6%). 
Thirty three patients considered as thalassemia intermedia on clinical base (as they received first blood 
transfusion older than two years of age as well as their needs to blood transfusion is less than major). 
 
Mutations: 
IVS 1.116 [T>G] mutation: 
This mutation was detected in 42 patients (39.6%), which is highest percent. More than three quarter of the 
patient were have family history of thalassemia and consanguinity marriage. As this mutation detected more in 
thalassemia major, it was detected in (73.8%). And mainly in male gender (66.7%). 
In spite of this mutation is Mediterranean mutation and one of mutation that frequently occur in 
Iranians peoples, (14). But unfortunately most studies which done in Iraq didn’t chose IVS 1. 116 as panel for 
screening thalassemia mutation. And didn’t reported in north Iraq study (15).  
This mutation was reported in Turkey thalassemia patients in (1.6%), (16). And in Syria (1.4%),  also 
detected in Egyptian patients in (1.2%), (17). Which is lower than what reported in this study.  
IVS 1.110 [G>C] : 
This mutation  was reported in this study in 14 (13.2%) patients, (64%) of them were have family history of 
thalassemia, more than 80% of them have consanguinity marriage, and thalassemia intermedia was reported in 
more than one half (57%). This mutation was reported equally in females and  male (50%). 
IVS 1. 110 [G>C] mutation was reported in about 18% thalassemia patients in Baghdad study, (18)  and 
27% in Ninawa  study (19). which is more than what reported in this study. This mutation was detected in 25% of 
Jordanian thalassemia patients (20) which is high to what reported in our study.  And reported 10% percent in 
Iranian patients (22). Which is lower than what reported in this study.  
IVS 1.5 [G>C] mutation:  
This mutation was reported in seven patients (6.6%), most of them were have family history of thalassemia, all 
of them were have consanguinity marriage and thalassemia major. This mutation have been equally reported in 
both gender. 
IVS 1.5 [G>C] Mutation was reported in 2% in Ninawa  study (19),which is lower than what reported in 
this study. While in Al muthana study was reported in 10% (18). And reported in 2% in Turkey study (21). 
Codon5[-CT] mutation : 
This mutation was reported in five patients (4.7%). Eighty percent of the patients with this mutation were have 
family history of thalassemia, consanguinity marriage and thalassemia major, this mutation were reported more 
in female (60%).  
This mutation was not reported in Baghdad, Mothanna, and north Iraq studies, but reported in Iran 
study in (3.8%) of thalassemia patients, (22). And reported in 0.5% in Turkey study (21). 
This mutation was detected in 3.8 % of Jordanian thalassemia patients (20). 
Codon 8/9 (+G) mutation: 
This mutation was reported in three patients (2.8%). All patients with this mutation were thalassemia major 
(100%). This mutation were not reported in north Iraq, Mothanna, Ninawa and Iran studies. But in other study in 
Baghdad done by Al-Azzawi  the percent is (7.7%)(23). In Turkey study the percent is (2.1%) (21). 
Others mutation which reported in one patients for each, -30 [T>A], Codon 39 [C>T], IVS 1.5 [A>C] 
as -30 [T>A] mutation were reported in Turkey patients in 4.6%, (21).Codon 39 [C>T] mutation were reported in 
Turkey patients in 3.6%, (21).And 4.9% in Jordanian patients, (20).15% in Al Muthana study, (18) . And 1%  in 
Baghdad study, (18). 
Conclusion : Conclusions: Many mutations record a high frequency due to close relative marriage. By 
analyzing many mutations in β-globin gene leading to defect in beta chains play crucial role in drawing mutation 
frequency and their distribution in our society. 
β-thalassemia is very common in Iraqi society, due to high consanguinity rates. 
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